EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Open Access · CC BY 4.0

Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia

Andrew J S Coats, Stefan D Anker, Lars H Lund, Gerasimos Filippatos, Patrick Rossignol, Bertram Pitt, Matthew R Weir, Mikhail N Kosiborod, Marco Metra, Michael Böhm, Justin A Ezekowitz, Antoni Bayes-Genis und 12 weitere

JACC: Heart Failure · 2024-12 · 12 (12) · 2026-2037

DOI: 10.1016/j.jchf.2024.08.003 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JACC: Heart Failure, 2024-12. Verfasst von Andrew J S Coats und 23 weiteren Autor:innen. Beteiligte Einrichtung: Heart Research Institute, Sydney, New South Wales, Australia. Electronic address: ajscoats@aol.com. Hauptthemen laut MEDLINE: Hyperkalemia, Heart Failure, Polymers, Mineralocorticoid Receptor Antagonists. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 21 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: For heart failure with reduced ejection fraction (HFrEF), suboptimal use of renin-angiotensin-aldosterone system inhibitors (RAASis), including mineralocorticoid receptor antagonists (MRAs), due to hyperkalemia, may be improved by potassium binders. OBJECTIVES: This prespecified analysis of the phase 3 DIAMOND (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure) trial assessed the effect of patiromer in patients with HFrEF and either current or past hyperkalemia. METHODS: Patients with HFrEF and current or past (within 1 year before enrollment) hyperkalemia (serum potassium [sK+] >5.0 mmol/L) entered a single-blind, run-in phase to optimize RAASis while receiving patiromer. They were subsequently randomized, double-blind, to continue patiromer or change to placebo. RESULTS: Of the 1,038 patients who completed run-in, 354 (83.9%) of 422 with current hyperkalemia and 524 (85.1%) of 616 with past hyperkalemia achieved RAASi optimization and were randomized to treatment. During the double-blind phase, patiromer lowered sK+ levels compared with placebo in both the current and past hyperkalemia subgroups: difference in adjusted mean change from baseline: -0.12 (95% CI: -0.17 to -0.07) and -0.08 (95% CI: -0.12 to -0.05), respectively; Pinteraction = 0.166. Patiromer was more effective than placebo in maintaining MRA at target dose in patients with current vs past hyperkalemia (HR: 0.45 [95% CI: 0.26-0.76] vs HR: 0.85 [95% CI: 0.54-1.32]; Pinteraction = 0.031). Adverse events were similar between subgroups. CONCLUSIONS: The use of patiromer facilitates achieving target doses of RAASis in patients with HFrEF with either current or past hyperkalemia. For those with current hyperkalemia before RAASi optimization, use of patiromer may be more beneficial in helping to maintain sK+ control and achieve MRA target dose. (Patiromer for the Management of Hyperkalemia in Subjects Receiving RAASi Medications for the Treatment of Heart Failure [DIAMOND]; NCT03888066).

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperkalemiaHeart FailurePolymersMineralocorticoid Receptor AntagonistsHumansMaleFemaleDouble-Blind MethodAgedMiddle AgedSingle-Blind MethodAngiotensin-Converting Enzyme InhibitorsStroke VolumePotassiumRenin-Angiotensin SystemTreatment Outcome

Stichwörter der Autor:innen

heart failure with reduced ejection fractionhyperkalemiapatiromerpotassium binderrenin-angiotensin-aldosterone system inhibitor

Substanzen

patiromerPolymersMineralocorticoid Receptor AntagonistsAngiotensin-Converting Enzyme InhibitorsPotassium

Autor:innen und Institutionen

  • Heart Research Institute, Sydney, New South Wales, Australia. Electronic address: ajscoats@aol.com.
  • Department of Cardiology (CVK) of German Heart Center Charité, Berlin Institute of Health Center for Regenerative Therapies (BCRT), German Centre for Cardiovascular Research (DZHK) partner site Berlin, Charité Universit…
  • Department of Medicine, Unit of Cardiology, Karolinska Institutet, Solna, Department of Cardiology, Karolinska University Hospital, Stockholm, Sweden.
  • National and Kapodistrian University of Athens, School of Medicine, Athens University Hospital Attikon, Athens, Greece.
  • Université de Lorraine, Centre d'Investigations Cliniques-Plurithématique 14-33, Inserm U1116, CHRU Nancy, and F-CRIN INI-CRCT (Cardiovascular and Renal Clinical Trialists), Nancy, France; Medical Specialties and Nephro…
  • Division of Cardiology, University of Michigan, Ann Arbor, Michigan, USA.

Zitieren

APA

Coats, A. J. S., Anker, S. D., Lund, L. H., Filippatos, G., Rossignol, P., Pitt, B., Weir, M. R., Kosiborod, M. N., Metra, M., Böhm, M., Ezekowitz, J. A., Bayes-Genis, A., Mentz, R. J., Ponikowski, P., Senni, M., Cleland, J. G. F., Goudev, A., Khintibidze, I., Lindenfeld, J., …, & Butler, J. (2024). Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia. JACC: Heart Failure, 12(12), 2026-2037. https://doi.org/10.1016/j.jchf.2024.08.003

Vancouver

Coats AJS, Anker SD, Lund LH, Filippatos G, Rossignol P, Pitt B, et al. Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia. JACC: Heart Failure. 2024;12(12):2026-2037. doi:10.1016/j.jchf.2024.08.003

BibTeX
@article{Coats2024,
  author = {Coats, Andrew J S and Anker, Stefan D and Lund, Lars H and Filippatos, Gerasimos and Rossignol, Patrick and Pitt, Bertram and Weir, Matthew R and Kosiborod, Mikhail N and Metra, Marco and Böhm, Michael and Ezekowitz, Justin A and Bayes-Genis, Antoni and Mentz, Robert J and Ponikowski, Piotr and Senni, Michele and Cleland, John G F and Goudev, Assen and Khintibidze, Irakli and Lindenfeld, Joann and Merkely, Bela and Waechter, Sandra and Budden, Jeffrey and Perrin, Amandine and Butler, Javed},
  title = {Patiromer for Heart Failure Medication Optimization in Patients With Current or Past Hyperkalemia},
  journal = {JACC: Heart Failure},
  year = {2024},
  volume = {12},
  number = {12},
  pages = {2026--2037},
  doi = {10.1016/j.jchf.2024.08.003}
}
Kostenlos starten →